Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection
Manuela Ceccarelli, Emmanuele Venanzi Rullo, Massimiliano Berretta, et al.
Dermatologic Therapy (2020) Vol. 34, Iss. 1
Open Access | Times Cited: 25

Showing 25 citing articles:

The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Rohan Singh, Sindhuja Koppu, Patrick O. Perche, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12793-12793
Open Access | Times Cited: 110
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study
Boni E. Elewski, Mark Lebwohl, Milan J. Anadkat, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 1, pp. 36-44
Closed Access | Times Cited: 27
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober, Laura C. Coates, Mark Lebwohl, et al.
Drug Safety (2023) Vol. 47, Iss. 1, pp. 39-57
Open Access | Times Cited: 27
Liposomes encapsulating novel antimicrobial peptide Omiganan: Characterization and its pharmacodynamic evaluation in atopic dermatitis and psoriasis mice model
Ankit Javia, Ambikanandan Misra, Hetal Thakkar
International Journal of Pharmaceutics (2022) Vol. 624, pp. 122045-122045
Closed Access | Times Cited: 33
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease
Alfonso Motolese, Manuela Ceccarelli, Laura Macca, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 228-228
Open Access | Times Cited: 29
Efficacy and safety of total glucosides of paeony in the treatment of 5 types of inflammatory arthritis: A systematic review and meta-analysis
Kailin Yang, Liuting Zeng, Zhiyong Long, et al.
Pharmacological Research (2023) Vol. 195, pp. 106842-106842
Open Access | Times Cited: 19
Therapies with Antioxidant Potential in Psoriasis, Vitiligo, and Lichen Planus
Fabrizio Guarneri, Lucrezia Bertino, Giovanni Pioggia, et al.
Antioxidants (2021) Vol. 10, Iss. 7, pp. 1087-1087
Open Access | Times Cited: 30
Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data
Lingqing Ding, Congqin Chen, Y. Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval
Eran C. Gwillim, Anna Nichols
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Exploration of Biomarkers of Psoriasis through Combined Multiomics Analysis
Lu Xing, Tao Wu, Li‐Rong Yu, et al.
Mediators of Inflammation (2022) Vol. 2022, pp. 1-25
Open Access | Times Cited: 17
Psoriasis and cancer: experience of using IL-17 inhibitor in a patient with severe psoriasis and a history of prostate cancer
E.V. Svechnikova Svechnikova, S. Е. Zhufina
Meditsinskiy sovet = Medical Council (2025), Iss. 2, pp. 50-58
Open Access
Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies
Salvatore Crisafulli, Lucrezia Bertino, Andrea Fontana, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 21
IL-33 and IL-37: A Possible Axis in Skin and Allergic Diseases
Francesco Borgia, Paolo Custurone, Federica Li Pomi, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 372-372
Open Access | Times Cited: 14
Genetically predicted ankylosing spondylitis is causally associated with psoriasis
Di Tian, Yuan Zhou, Yu‐Ting Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments
Federica Li Pomi, Laura Macca, Alfonso Motolese, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1594-1594
Open Access | Times Cited: 17
Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies
Laura Cannon, Alice Pan, Leonard Kovalick, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 6, pp. 718-726
Open Access | Times Cited: 7
Exploration of biomarkers of psoriasis through combined multiomics analysis
Lu Xing, Li‐Rong Yu, Nian Zhou, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 5
Multimorbid pathology at psoriasis (scientific review)
Timur Z. Alikbaev, Sergey A. Sayganov, K. I. Raznatovskiy
HERALD of North-Western State Medical University named after I I Mechnikov (2024) Vol. 16, Iss. 2, pp. 19-26
Open Access
Starting and Maintaining Patients on Biologics and Janus Kinase Inhibitors for Various Immune-mediated Inflammatory Dermatologic Conditions
Clarisse G. Mendoza, C.S. de Jesus, Ma. Corazon Iniego-Rodas
Deleted Journal (2024) Vol. 33, Iss. 2, pp. 47-52
Closed Access
Long-term efficacy of biologic treatment for psoriasis after COVID-19 infection
K. Bakirtzi, Ilias Papadimitriou, Efstratios Vakirlis, et al.
Clinical and Experimental Dermatology (2022) Vol. 47, Iss. 11, pp. 2025-2026
Open Access | Times Cited: 2
Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks
Xi‐Bei Chen, Yuxin Zheng, Li‐Ran Ye, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 12
Open Access | Times Cited: 2
Psoriatic arthritis and psoriasis in the era of COVID-19
Panagiotis Athanassiou, Lambros Athanassiou, Ifigenia Kostoglou‐Athanassiou
Elsevier eBooks (2023), pp. 557-565
Closed Access
Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study
Mia‐Louise Nielsen, T. C. Petersen, Julia‐Tatjana Maul, et al.
JEADV Clinical Practice (2023) Vol. 2, Iss. 4, pp. 792-801
Open Access
Netakimab in the therapy of psoriatic onychodystrophy
О. В. Жукова, S. I. Artemyeva, Al-Hawatmi Ahmad, et al.
Meditsinskiy sovet = Medical Council (2022), Iss. 13, pp. 18-23
Open Access
Changes in mononuclear cell subsets in capillary and venous blood of patients with psoriasis depending on the treatment
S. V. Sennikova, А. П. Топтыгина
Russian Journal of Immunology (2022) Vol. 25, Iss. 4, pp. 521-528
Open Access
Page 1

Scroll to top